Supernus, Inc. (INDV) stock
INDVNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SUPN
$35.37+0.12 (+0.34%)
Close on Oct 30, 2026Market cap $4.17BP/E 9.9Yield –
Supernus ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Supernus's ebitda for the twelve months ending Sep 30, 2026 was $565.00M, up 135.4% year over year. For fiscal 2025 it was $272.00M, up 403.7% from the year before. The highest annual figure on record is $272.00M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $272.00M | +403.7% |
| FY2024 | Dec 31, 2024 | $54.00M | – |
| FY2023 | Dec 31, 2023 | -$137.00M | – |
| FY2022 | Dec 31, 2022 | -$61.00M | -126.8% |
| FY2021 | Dec 31, 2021 | $228.00M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $181.00M | +293.5% |
| Q2 FY2026 | Jun 30, 2026 | $162.00M | +118.9% |
| Q1 FY2026 | Mar 31, 2026 | $139.00M | +101.4% |
| Q4 FY2025 | Dec 31, 2025 | $83.00M | +62.7% |
| Q3 FY2025 | Sep 30, 2025 | $46.00M | +17.9% |
| Q2 FY2025 | Jun 30, 2025 | $74.00M | – |
| Q1 FY2025 | Mar 31, 2025 | $69.00M | -13.7% |
| Q4 FY2024 | Dec 31, 2024 | $51.00M | – |
| Q3 FY2024 | Sep 30, 2024 | $39.00M | – |
| Q2 FY2024 | Jun 30, 2024 | -$116.00M | – |
| Q1 FY2024 | Mar 31, 2024 | $80.00M | – |
See a number that looks wrong?